Ask AI
ProCE Banner Activity

DESTINY-Gastric04: T-DXd vs Ramucirumab + Paclitaxel as Second-line Therapy in HER2+ Unresectable/Metastatic Gastric Cancer/GEJ Adenocarcinoma

Conference Coverage
Slideset

In the phase III DESTINY-Gastric04 trial, trastuzumab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in OS compared with ramucirumab plus paclitaxel as second-line therapy for patients with HER2+ unresectable/metastatic GC/GEJA.

Released: June 05, 2025

Expiration: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group